Indeed, blocking human PVRIG in tumor-bearing humanized mice resulted in smaller tumor sizes, indicating the therapeutic value of anti-hPVRIG mAb, meanwhile, pointing out that anti-hPVRIG mAb could be effective by acting only on NK cells. Here, PVRIG is linked to neoplasm.